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dhoice of Prosthetic Heart Valves: 20-Year
esults of the Edinburgh Heart Valve Trial
recent edition of the Journal carried a robust debate between
avid S. Bach (1) and Shahbudin H. Rahimtoola (2) on the choice
f prosthetic heart valves for individual patients requiring valve
eplacement surgery. Bach’s (1) thesis was that prosthetic heart
alves have evolved over the years to provide superior hemody-
amics and durability compared to older valves, which had been
ncluded in randomized trials. Rahimtoola’s (2) commentary, “The
ext generation of prosthetic heart valves needs a proven track
ecord of patient outcomes at 15 to 20 years,” emphasized the
mportance of obtaining long-term data not available for the newer
rostheses, and he stressed how important long-term data are from
rospective randomized trials.
Bach (1) notes that in the Edinburgh Heart Valve Trial there
as a trend favoring improved survival in association with the
echanical Bjork-Shiley prosthesis. We have recently published
ata from the 20-year follow-up of patients randomized in this
rial. Interestingly, the trend toward improved survival at 12 years
iminished as patients were followed for 20 years. Bach (1) also
oted, “However, freedom from all valve-related complications for
issue and mechanical prostheses was indistinguishable at 12
ears.” In fact, when we followed our patients for survival without
major event (i.e., freedom from death, re-operation, major
emorrhage, embolism, or endocarditis) there was a significantly
etter survival in favor of the Bjork-Shiley prosthesis for those
ndergoing mitral valve replacement (3). This benefit became
pparent after 10 to 12 years of follow-up and as survival cures
ontinued to separate thereafter.
This difference in survival without a major event was almost
ntirely accounted for by the increased need for re-operation in
atients who had received a bioprosthesis with increasing years of
ollow-up. There was no significant difference in survival without
major event in the subgroup of patients who had undergone
ortic valve replacement. These results would not support Bach’s
1) statement, namely that “Bioprostheses were superior to me-
hanical valves prior to 12 years after surgery and were equivalent
hereafter.” The risk of anticoagulant hemorrhage is of course not
imited to those patients receiving a mechanical valve. We noted an
ncrease in the use of anticoagulants in patients who had been
andomized to receive a bioprosthesis during the course of the trial.
t five years, 15% of patients with a porcine aortic prosthesis and
6% of those with a porcine mitral prosthesis were receiving
arfarin; by 15 years this proportion had risen to 33% and 57%,
espectively. The increasing use of warfarin with the passage of
ime reflected concomitant conditions such as atrial fibrillation and
hamber dilation favoring the use of long-term anticoagulation.
These results emphasize the need for prolonged follow-up of
atients in randomized trials of prosthetic heart valves as it is only
ith such prolonged follow-up that important differences between
rostheses are seen to emerge. It is perhaps ironic that data from
he Edinburgh Trial and the U.S. Department of Veterans Affairs
rial have provoked such debate within the editorial pages of the
ournal of the American College of Cardiology. We had submitted the
anuscript of the 20-year follow-up to the Journal more than a
ear prior to Bach’s (1) viewpoint and Rahimtoola’s (2) commen-
ary and previous editorial. The Journal declined our manuscript; Ccceptance may have cast more light than heat on the subsequent
ebate.
eter Bloomfield, MD
oyal Infirmary of Edinburgh
Lauriston Place
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cotland
nited Kingdom
-mail: peter.bloomfield@luht.scot.nhs.uk
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EPLY
am glad Dr. Bloomfield concurs with and re-emphasizes the
mportance of obtaining long-term (15 to 20 years) follow-up
ata in patients with prosthetic heart valves (PHVs). The 20-year
esults of the Edinburgh Heart Valve trial (1) (Edinburgh trial) are
eviewed in the Journal of the American College of Cardiology series
ntitled “The Year in Cardiology” (2). This trial showed that at 20
ears the incidence of re-operation in patients receiving the porcine
HV was very much higher than in patients receiving the
echanical PHV; after mitral valve replacement it was 77.6%
ersus 13.4%  p  0.0001 (1), and after aortic valve replacement
t was 56.2% versus 7.4%, p  0.0001. In the Veterans Affairs (3)
nd Edinburgh trials (1), major differences between the mechanical
nd bioprostheses that were statistically significant appeared after
bout 10 to 12 years of follow-up.
I agree that the Edinburgh and Veterans Affairs trials are very
mportant and provide useful data, but they should not be used as
he sole source on which to choose a PHV (3–5). In the Edinburgh
rial (1), at 20 years the survival with original prosthesis intact was
etter with mechanical valve, but the total mortality was not
ignificantly different between a mechanical and porcine PHV.
oncardiac causes accounted for 23% to 28% of the deaths; data
PHV vs. non-PHV) on the cardiac causes of death in those with
echanical and porcine PHVs are not provided. This information
ight help to understand why all-cause mortality was not signif-
cantly different. It is of interest that the 30-day mortality of
e-operation was 14.2% (18.3% before 1987 and 9.4% after 1987)
1).
Finally, the review (4) had not dealt with stentless PHVs in any
etail because long-term follow-up data was not available. The
ommentary (5) was able to show that Dr. Bach’s (6) unbridled
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August 4, 2004:667–70nthusiasm for the stentless porcine valve was not supported by the
vailable data.
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EPLY
n Dr. Bloomfield’s letter discussing the Viewpoint (1) and
ommentary (2) recently published in the Journal, Dr. Bloomfield
otes that, in long-term follow-up of the Edinburgh Heart Valve
rial (3), 1) mortality at 20 years did not differ between mechanical
nd tissue prostheses; 2) owing to differences in rates of re-
peration, freedom from all valve-related complications was supe-
ior after mechanical mitral (but not aortic) valve replacement; and
) over time, an increasing use of anticoagulant therapy was seen
fter tissue valve replacement. Dr. Bloomfield concludes that
ong-term follow-up of patients in randomized trials is the only
eans by which differences between prostheses can be elucidated.
Equivalence of mortality at 20 years supports that, using this
nd point, existing data (including those from the Edinburgh
eart Valve Trial) do not favor one prosthesis type over another.
reedom from all valve-related complications favors neither pros-
hesis type following aortic valve replacement, which comprises a
reponderance of valve replacement surgeries in the United States;
or both mitral and aortic valves, higher rates of re-operation after
issue compared with mechanical valve replacement exemplifies an
nherent difference between prostheses. However, re-operation
ay be an end point more universally feared by cardiologists than
y patients. Operative mortality for elective “re-do” valve replace-
ent is not substantially different from that for initial surgery.
hereas some patients may wish to avoid re-operation at all costs,
thers are clearly willing, if given the option, to face the near-
ertainty of additional surgery in order to avoid daily anticoagula-
ion. This argument is not obviated by an early experience showing
ncreasing requirement over time for anticoagulation due to atrial
brillation. Atrial fibrillation carries a lower thromboembolic risk wand therefore requires less aggressive anticoagulation) compared
ith mechanical mitral valve replacement. Moreover, earlier inter-
ention as well as newer medical therapies and surgical and
ercutaneous procedures presently available for the treatment of
trial arrhythmias can be expected to lower the need for additional
ong-term anticoagulation compared with the cohort studied from
he 1970s.
The tenet of the previously published Viewpoint (1) is not that
ong-term data are not desirable, but that for prosthetic valve
hoices that are made today, pertinent long-term, randomized data
o not (and will never) exist. Although Dr. Bloomfield and his
o-investigators (3) are to be commended for their study, the data
s they relate to current decisions in prosthetic valve surgery are
oot. In 2004, neither the Bjork-Shiley nor the original Hancock
alve is available for implantation. Future randomized studies are
nrealistic, and even if performed, valve technology would again
ave evolved by the time long-term data became available. Rather
han attempting to extrapolate to current practice “tissue versus
echanical” data from valves that are obsolete and in some cases
nown to be poorly representative of currently available prostheses,
his author asks the clinician to understand the limitations of these
ata, and to recognize that the gradual and continuing advances
ade in heart valve prostheses make a demand for only long-term,
andomized data unrealistic and therefore unwise.
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ncreased Randomness of
eart Rate Could Explain
ncreased Heart Rate Variability
receding Onset of Atrial Fibrillation
he recent study in JACC by Amar et al. (1) describes significant
ncreases in heart rate variability (HRV) in the period preceding
he onset of atrial fibrillation (AF) in postoperative patients. This
ncrease in HRV is interpreted by the investigators as reflecting
ncreased parasympathetic and sympathetic activity. Whereas this
s a possible explanation, another equally plausible explanation
equires testing. We propose that the increase in HRV is due to an
ncrease in the randomness of the heart-period signal, associated
ith a marked increase in sympathetic activation. This would be
